New hope for itchy eyelids? drug trial targets stubborn rash
NCT ID NCT06684522
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a pill called upadacitinib for people with eyelid dermatitis that hasn't gotten better with standard creams. Ten adults aged 18-70 will take the drug for 12 weeks to see if it reduces redness and irritation. The goal is to find a new option for those who haven't had success with other treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EYELID DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Northwestern University Department of Dermatology
RECRUITINGChicago, Illinois, 60611, United States
Contact Email: •••••@•••••